ASCO 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), Intravesical Sacituzumab Tirumotecan, Intermediate-Risk Non–muscle-Invasive Bladder Cancer, TroFuse-027 Study, Trophoblast cell-surface antigen 2 ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).

AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...

PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.

SNMMI 2025 utility of the PROSTest to predict response to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC), blood-based 27-marker gene mRNA expression machine ...

Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.

Alan Bryce hosts Mary-Ellen Taplin to discuss key recommendations from the 2024 US Prostate Cancer Consensus Conference addressing biochemical recurrence management. Dr. Taplin emphasizes that PSMA ...

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. July 18, 2025 Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

Neeraj Agarwal speaks with Praful Ravi about an individual patient data meta-analysis examining docetaxel addition to ADT plus radiation therapy in high-risk localized prostate cancer. The ISECaP ...